Milestone payments from CTF will support advance of Healx’s lead compound, HLX-1502, to clinical trials and broader Neurofibromatosis Type 1 program Investment reinforces long-term, patient-focused partnership combining Healx’s proprietary AI-powered drug discovery platform with CTF’s…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.